TEDA Releases Policies for the High-Quality Development of the Biopharmaceutical Industry
On May 14th, during the 7th World Intelligence Congress Sub-forum, the “Advanced Manufacturing Development Conference for Bulk Pharmaceutical Chemicals and Pharmaceutical Intelligent Manufacturing Summit,” TEDA released policies for the high-quality development of the biopharmaceutical industry. The policies aim to support the development of the biopharmaceutical industry through key area innovation, technology platform construction, industry carrier support, and financial services.
In terms of supporting innovation in key areas, TEDA plans to establish China’s largest and world-class nucleic acid industry hub, creating specialized parks covering nucleic acid drugs, vaccines, pharmaceutical equipment, and other segments of the industry chain. Eligible enterprises can receive funding rewards of up to 25 million yuan. The development of the medical device industry towards innovation and intelligence is also encouraged, with eligible enterprises receiving funding rewards of up to 15 million yuan. Research and development innovation and pharmaceutical outsourcing will be supported, with eligible enterprises receiving funding rewards of up to 20 million yuan.
Regarding the construction of technology platforms, the policies support exhibitions and exchanges of imported pharmaceutical and medical device, strengthen patent and technical services, promote integration of industry and education. Research and development transformation and professional talent development will be encouraged as well.
In terms of building industry carriers, projects such as the TEDA Biotechnology Innovation Park and Beijing-Tianjin-Hebei Intelligent Pharmaceutical Industry Park will be initiated. The establishment of drug R&D and pilot-scale experiment focused areas, the creation of a high-end medical device industry park integrating artificial intelligence and medical devices, the establishment of a small nucleic acid production base, and the construction of an bulk pharmaceutical chemicals pilot-scale experiment are planned.
To strengthen financial services, the policies encourage the full utilization of financial institutions and related resources within the area to provide services to enterprises in financing, guarantees, listing, and other aspects.
First, please LoginComment After ~